Need for a New Framework to Understand the Mechanism of All Antipsychotics
J Clin Psychiatry 2000;61:387-388 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: The advent of atypical neuroleptics has transformed the
pharmacologic treatment of schizophrenia. The advent of single
photon emission computed tomography (SPECT) and positron
emission tomography (PET) neuroreceptor imaging makes it
possible to link biochemical events in the human brain to their
clinical consequences. Remington and Kapur (supplement 10,
1999) have proposed an interesting model based on studies using
PET that takes in account the serotonin-2/dopamine-2
(5-HT2/D2) occupancy threshold: conventional antipsychotics
have low 5-HT2/high D2 ratios, olanzapine and risperidone have
high 5-HT2/high D2 ratios, clozapine has a high 5-HT2/low D2
ratio, and quetiapine has a low 5-HT2/low D2 ratio. Beyond
80% of D2 blockade, extrapyramidal symptoms appear. To attain
optimal blockade, 2 to 4 mg/day of a conventional neuroleptic
such as haloperidol is sufficient.